LXRX Lexicon Pharmaceuticals, Inc.

14.41
-0.15  -1%
Previous Close 14.56
Open 14.48
Price To book 11.38
Market Cap 1.52B
Shares 105,235,000
Volume 861,836
Short Ratio 12.34
Av. Daily Volume 901,345

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Secondary endpoint data from first trial due May 2017. Data from third trial due mid-2017.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Sotagliflozin
Type 2 Diabetes

Latest News

  1. ETFs with exposure to Lexicon Pharmaceuticals, Inc. : May 23, 2017
  2. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : May 18, 2017
  3. Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes
  4. Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
  5. Edited Transcript of LXRX earnings conference call or presentation 2-May-17 10:00pm GMT
  6. Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Healthcare Conference
  7. Lexicon reports 1Q loss
  8. Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update
  9. Lexicon Pharmaceuticals To Host First Quarter 2017 Financial Results Conference Call And Webcast On May 2, 2017
  10. Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : April 26, 2017
  11. ETFs with exposure to Lexicon Pharmaceuticals, Inc. : April 25, 2017
  12. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 25, 2017
  13. 3 Top Biotech Stocks to Buy in April
  14. Lexicon To Present At The 16th Annual Needham Healthcare Conference
  15. What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
  16. 3 Tremendously Promising Diabetes Drugs Potentially on the Way
  17. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : March 20, 2017
  18. Surging Earnings Estimates Signal Good News for Lexicon (LXRX)
  19. Lexicon To Present At The Barclays Global Healthcare Conference